PL02.04 Ivonescimab (AK112) 与 Pembrolizumab 作为 PD-L1 阳性晚期 NSCLC 一线治疗的 3 期研究：HARMONi-2 的初步分析

IF 21 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI:10.1016/j.jtho.2024.09.012

C. Zhou , J. Chen , L. Wu , L. Wang , B. Liu , J. Yao , H. Zhong , J. Li , Y. Cheng , Y. Sun , H. Ge , Q. Shi , M. Zhou , Z. Han , J. Wang , Q. Bu , Y. Zhao , J. Chen , J. Yang , M. Xia

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.